Conclusions: Inhibition of AKT can effectively decrease RSV replication in culture, likely by decreasing P phosphorylation and thus viral protein transcription and expression. Activation of AKT during RSV infection likely involves the NS2 protein and does not depend on the PH domain of AKT. AKT inhibitors have been found to be safe and efficacious in clinical trials for a number of different cancers; thus, AKT inhibition may be a potential therapeutic treatment for severe RSV infection. Background: Viruses and bacteria are important contributors to asthma exacerbations. Exercise at competitive level is believed to increase susceptibility to respiratory infections. The study aimed at investigation of the antiinfectious immune response in athletes in the context of exercise intensity, atopy and allergic diseases. Methods: Questionnaire data were obtained from 219 Polish athletes (median age 26 years) preparing for Beijing Olympic Games during the multicenter study within the GA 2 LEN project (WP 2.8.2). Allergy Questionnaire for Athletes (AQUA) (Bonini et al 2009) was used to obtain data about symptoms and exercise pattern. Athletes were evaluated by allergist. Control group consisted of 77 healthy never-smokers (median age 29 years) not performing sport at competitive level. Serum IgG against parainfluenza virus 1,2 and 3 (PIV), respiratory syncytial virus (RSV), adenovirus and Mycoplasma pneumoniae were determined by ELISA. Results: Percentage of athletes with positive serological testing was lower than percentage of HC in case of PIV (P , 0.0003), RSV (P ¼ 0.01) and M. pneumoniae (P ¼ 0.01). Analysis of IgG only in subjects with positive testing showed lower anti-PIV IgG levels in non-atopic athletes compared to HC (P , 0.001) and atopic athletes (P , 0.01) (median 66.0 vs 104.8 and 88.1 U/ mL). In contrast, higher adenovirus IgG titres were found in atopic and nonatopic athletes as compared to HC (52.3 and 48.5 vs 36.6 EIU, P , 0.001). Positive anti-PIV serology test was most frequent in athletes with allergic rhinitis compared to asthmatic and healthy athletes (78.3 vs 50.0 and 46.8%; P ¼ 0.002). For PIV and M. pneumoniae the difference was also seen when atopic and non-atopic athletes were compared separately with HC. Positive RSV serology was more frequent in atopic versus non-atopic athletes (76.3 vs 60.8%, P ¼ 0.03) and in HC versus non-atopic athletes (84.4 vs 60.8%, P ¼ 0.001) but no significant difference between atopic athletes and HC was seen. Positive RSV serology was associated with atopy (OR 2.89; 95% CI, 1.34-6.23; P ¼ 0.007). No differences were observed with regard to exercise pattern (endurance vs non-endurance). Conclusions: Competitive sport at Olympic level may be associated with altered immune response against respiratory pathogens. For some agents this response may be affected by the atopic status.
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The Immune Response Against Respiratory Pathogens in Patients with Chronic Rhinosinusitis/Nasal Polyps and Asthma with or without Sensitivity to Aspirin Agnieszka Olszewska-Ziaber, MD, PhD, Marzanna Jarzebska, and Marek L. Kowalski, MD, PhD. Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Łód z, Poland. Background: Viral and bacterial infections can modulate the ongoing inflammation in both upper and lower airways of patients with chronic rhinosinusitis with nasal polyps (CRS/NP) and asthma. It was not clear if the protective immune response to pathogens may differ depending on the disease severity.Object: To compare serum IgG immune response against respiratory pathogens in patients with chronic airway disease (CRS/NP and asthma) with and without sensitivity to aspirin, and to refer the sensitization to severity of chronic rhinosinusitis. Methods: We recruited 73 patients with CRS/NP and asthma with (43 patients) and without (30 patients) hypersensitivity to aspirin. The extent of mucosal hypertrophy in paranasal sinuses was assessed by CT scans and the sense of smell was valuated with "sniffing smell" test. Serum IgG immunoglobulin levels against respiratory pathogens: Respiratory Syncytial Virus (RSV), Adenowirus (ADV), Parainfluenza virus (PIV) and Mycoplasma pneumoniae were determined by ELISA. Results: Patients with ASA-hypersensitivity had history of significantly more nasal polypectomies (P ¼ 0.002), lower smell test score (P ¼ 0.03) and higher mean paranasal CT score (P ¼ 0.03) as compared to ASA-tolerant patients, reflecting higher severity of the upper airway disease. The percentage of positive serological testing to respiratory pathogens was very high in the whole group of patients with CRS/NP and asthma (RSV, 95.8%; ADV, 95.9%; PIV, 84.9% and Mycoplasma pneumonieae, 100% patients) without any difference between ASA-sensitive and ASA-tolerant subjects. Patients with ASA-sensitivity had significantly lower concentrations of PIV-specific IgG (mean 188.67 6 34.46 U/mL versus 207.56 6 30.036 U/mL; P , 0.04) as compared to ASA-tolerant subjects. There was a significant trend (P , 0.048) for lower PIV-specific IgG concentrations with increased number of polypectomies. No correlation of IgG immunoglobulin concentrations for other pathogens with the number of polypectomies, paranasal sinuses CT score or presences of smell were observed. Conclusions: Patients with CRS/NP and asthma had high frequency of IgG immunoglobulin against common respiratory pathogens. Serum IgG immune response to paramyxoviruses may be related to the recurrence of nasal polyps and the presence of aspirin sensitivity. Internal Medicine, Juarez Hospital Mexico City, Mexico. Mexico 2009 faced the H1N1VI influenza pandemic, a complex immunologic and clinical host response, whose defense mechanisms have yet to be identified. Lack of information on clinical an immunological features in pediatric population with H1N1VI, delay detection of patients at risk of contracting it. This study aims to identify specific immunologic and/or clinical features of pediatric patients with H1N1VI in a federal Hospital in Mexico City. Methods: Single-center, observational, non-experimental, prospective trail from September to October 2009, for pediatric patients arriving to Emergency room of Juarez Hospital, with suspicion of H1N1VI, needing to be younger than 17 years, and agree and sign the consent form by tutor. Samples obtained were peripheral blood, and pharyngeal exudate. From blood LS, Cytokine levels, and routine measurements (CBC, BCH) were investigated; the pharyngeal sample underwent PCR study to viral genetic material. Complementary studies such as arterial blood gases or Torax radiography were realized as needed. Results: 32 patients participated. PCR results confirmed 18 cases (56%), 1 patient resulted positive for SII. The average age was 9 years old; 12 (67%) were female, and 6 (33%) were male. The mean amount of days from symptom onset to receiving medical attention was 2.5 days. Main symptoms and signs were fever, malaise, cough, rhinorrhea, and headache. 
